Skip to Main Content
Alzheimer's Disease

Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI 4)

What is the purpose of this trial?

At present, the development of drugs for patients with Alzheimer’s disease is costly and time consuming. The validation of suitable biomarkers that track the progression of the disease and reflect underlying pathology is critical to streamlining this process. This is a multi-center observational research study designed to look at the relationships between clinical, cognitive, imaging, genetic, and biomarker tests in order to understand the full spectrum of Alzheimer’s disease (AD) from its earliest stage.

It will enroll about 1500 participants ages 55 – 90 (inclusive) across three cohorts: cognitively normal, mild cognitive impairment, and mild AD dementia. Approximately 750 of those participants will have also been in the ADNI-3 study. At least 50-60% of newly enrolled participants will come from populations that have been underrepresented in earlier iterations of ADNI (e.g., Black, Latinx, and persons with less than 12 years of education) to enhance the generalizability of results.

Study participation will last for about 4-5 years based on cohort (up to 6 visits total). All subjects will undergo MRI scans and up to 8 PET scans and can participate in optional lumbar puncture procedures (up to 3 lumbar punctures). They will also have the option to participate in a brain donation program.

  • Trial with
    University of Southern California
  • Ages
    55 years - 90 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Jesse Stanhope

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    08/02/2024
  • Study HIC
    #2000034800